How to track your Lp(a) over time
Lipoprotein(a), or Lp(a), is the odd one out in this series. For most lab tests, tracking means collecting results and watching the line. For Lp(a), most people need one good measurement in their lifetime. The 2026 ACC/AHA dyslipidemia guideline says it “should be measured at least once in adulthood,” and that “repeat testing is generally not needed.”
Plenty of people end up with several Lp(a) results anyway: one from a cardiologist, one from a direct-to-consumer panel, one from a lab abroad, one after starting a new drug. They often come in different units, and they rarely line up. This post is about keeping that handful of results honest: which differences mean something, which are the units talking, and when a new value is worth having.
What Lp(a) is
An Lp(a) particle is an LDL particle with a second protein, apolipoprotein(a), attached. That protein contains a repeating section, and the number of repeats is inherited and varies widely from person to person. The 2022 European Atherosclerosis Society consensus statement recommends testing Lp(a) at least once in adults, and the 2024 National Lipid Association update says the same. The NLA estimates that about 1 in 5 people have an elevated level.
Because your genes set most of it, Lp(a) barely responds to diet and exercise. The EAS panel says lifestyle changes have “minimal impact.” That is the reason one test is usually enough, and it is also why a high result matters for your family (see Family testing below).
Lp(a) carries cholesterol, so it is counted inside your total, non-HDL, and often your LDL cholesterol. Each Lp(a) particle also carries one ApoB, so it is counted in an ApoB result too. How to track your ApoB over time covers that test.
The numbers on the report
Lp(a) is reported in two units that measure different things. nmol/L counts particles. mg/dL weighs them, and the weight depends on how many repeats your particles carry. There is no single factor between them. The EAS panel “does not recommend using a standard factor to convert between mg/dL and nmol/L.” Read each result against the cutoffs for its own unit instead. Lp(a) in mg/dL and nmol/L explains why, and reads a result against those cutoffs for you.
| Reading | mg/dL | nmol/L |
|---|---|---|
| Low risk from Lp(a) | below 30 | below 75 |
| Intermediate or grey zone | 30 to 49 | 75 to 124 |
| High risk | 50 or above | 125 or above |
| Very high, similar to familial hypercholesterolemia (EAS) | above 180 | above 430 |
The low, intermediate, and high bands are the NLA’s and the EAS panel’s. The 2026 ACC/AHA guideline uses the same 125 nmol/L (50 mg/dL) line and says a level at or above it is “associated with about a 1.4-fold increased long-term risk of heart attack or stroke,” while 250 nmol/L is associated with “at least a two-fold” risk. The EAS panel also stresses that risk “increases continuously” with Lp(a). The cutoffs are practical lines, not a cliff.
Some European labs report mg/L. That is a mass unit and does convert: 300 mg/L is 30 mg/dL.
The EAS panel asks labs to use an assay “insensitive to apo(a) isoform” and to report in nmol/L where possible. Older mg/dL methods often were not, which is one more reason results from different labs and decades do not line up.
How often it is tested
- Once in adulthood, according to the 2026 ACC/AHA guideline, the 2024 NLA update, and the 2022 EAS statement. The EAS panel suggests doing it with the first lipid profile.
- In children and teenagers, only in specific situations, such as an ischemic stroke or a parent with early heart disease and no other explanation. The EAS panel notes that more than one test may be needed in youth, because levels can rise until adulthood.
- Again, for specific reasons. The EAS panel says repeat measurement is not required for risk prediction, but names conditions where levels shift, including kidney disease, liver disease, and acute infection. Those are covered below.
Large data back up the “once” advice. In the UK Biobank, 16,017 people had Lp(a) measured twice, a median of 4.4 years apart. The two results were very closely correlated (Spearman rho 0.96), and the change between them added nothing to predicting heart disease beyond the later value. The authors concluded that, without a treatment that substantially changes Lp(a), “a single accurate measurement” is an efficient way to inform risk.
Why you might have more than one result
A different lab or a different unit
The most common reason for two different numbers is not your body. It is two labs. One may report mg/dL and the other nmol/L, or both may report the same unit with methods that handle large particles differently. A result of 60 mg/dL and a later 140 nmol/L are both above the high-risk line. That is the comparison that holds up. Saying the second is “higher” is not meaningful.
Conditions that change Lp(a)
Lp(a) is stable, not fixed. The EAS consensus lists several situations that move it:
- Pregnancy: about a twofold increase.
- Menopause: levels tend to rise.
- Kidney disease: nephrotic syndrome raises Lp(a) 3 to 5 times compared with controls, and peritoneal dialysis about 2 times. After a kidney transplant, levels return toward normal.
- Liver disease: impaired liver function can lower it, depending on the cause.
- Inflammation: severe acute illness can lower it, while several chronic inflammatory conditions raise it.
- Underactive thyroid: raises Lp(a), and thyroid replacement lowers it by 5 to 20 percent.
If your one Lp(a) result came from any of these periods, it is reasonable to ask whether a repeat at a calmer time would be useful. Note the context next to the result either way.
Medications
Most cholesterol drugs leave Lp(a) alone or move it modestly:
- PCSK9 inhibitors lower Lp(a) by 15 to 30 percent, according to the EAS statement. In the FOURIER trial, evolocumab lowered it by a median of 26.9 percent at 48 weeks.
- Statins may raise Lp(a) slightly, if at all. In the UK Biobank study, statin use was associated with an increase among people who started at 70 nmol/L or above.
- Hormone therapy after menopause lowered Lp(a) by about 25 percent in the studies the EAS panel summarized.
- Niacin lowers Lp(a), but the EAS panel does not recommend it, “given the lack of clinical benefit in two outcomes studies.”
None of these is a treatment for Lp(a) as such. Their effect is a reason to note the medication with any Lp(a) drawn while you were taking it, and to compare a result on treatment with your untreated baseline carefully. Did the medication actually do anything? covers reading a before-and-after fairly.
Drugs made to lower Lp(a)
Several drugs designed to lower Lp(a) directly are in trials. They lower it far more than anything above: the EAS panel cites reductions of 72 to 80 percent for pelacarsen and 71 to 97 percent for olpasiran in early trials, and a phase 2 trial of zerlasiran reported average reductions of 81 to 86 percent over 36 weeks. What is not yet known is whether lowering Lp(a) prevents heart attacks and strokes.
As of November 2026:
- Pelacarsen (Novartis and Ionis). On September 4, 2026, Novartis announced that the Lp(a)HORIZON outcome trial, in 8,323 people with elevated Lp(a) and established heart disease, “did not meet its primary endpoint of reducing the risk of cardiovascular events,” although Lp(a) was lowered. As of this writing, the full results have not been published.
- Olpasiran (Amgen). The OCEAN(a)-Outcomes trial has enrolled 7,297 people and is no longer recruiting. Its estimated primary completion date is March 2028.
- Lepodisiran (Lilly). The ACCLAIM-Lp(a) trial is no longer recruiting, with an estimated primary completion date of March 2029.
- Zerlasiran (Silence Therapeutics) has completed the phase 2 trial above. No outcome trial is listed on ClinicalTrials.gov.
- Muvalaplin (Lilly), a pill, is recruiting for an outcome trial with an estimated primary completion date of March 2031.
No drug is approved specifically to lower Lp(a). If you join one of these trials, or one is approved, Lp(a) becomes a test worth charting: a baseline before, and results after. Keep the unit the same throughout, ideally at the same lab.
What counts as a real change
With so few results, the usual approach of comparing a new value against your spread does not work well. A few rules help:
- Compare results only within one unit. Never convert one to match the other.
- Ask whether the category changed. A move from 40 to 45 mg/dL stays in the grey zone. A move across 50 mg/dL or 125 nmol/L changes how the result is read, and is worth a repeat at the same lab before anything is decided.
- Look for a reason. A pregnancy, menopause, kidney disease, a new PCSK9 inhibitor, or a change of lab explains most differences.
- Expect stability otherwise. In the UK Biobank study, results years apart were ranked very nearly the same. A large change with no reason above is more likely to be a method difference than a change in you.
Family testing
Because Lp(a) is inherited, one high result says something about your relatives. The NLA update says “cascade screening of first-degree relatives of patients with elevated Lp(a) can identify additional individuals at risk.” The EAS panel suggests offering testing to first-degree relatives, meaning parents, siblings, and children, and recommends cascade testing alongside familial hypercholesterolemia or a family or personal history of heart disease.
If you keep lab results for a parent or child too, How to keep track of a parent’s lab results covers doing that separately from your own. Note on your own result whether relatives have been tested, and what they found.
What to record with each result
For each Lp(a) result, keep:
| Field | Why |
|---|---|
| Collection date | Needed to place it against life events and medications. |
| Value and unit | mg/dL, mg/L, and nmol/L. Only mg/L and mg/dL convert. |
| Lab and assay | Methods differ in how they handle large particles. |
| Category | Low, grey zone, or high, read against its own unit’s cutoffs. |
| Medications | PCSK9 inhibitors, statins, hormone therapy, niacin, or a trial drug, with dates. |
| Other context | Pregnancy, menopause, kidney or liver disease, a recent serious illness, thyroid treatment. |
| Family | Which relatives have been tested, and their results. |
Lp(a) appears on reports as Lp(a), Lipoprotein(a), and Lipoprotein (a). Pick one name, but keep the unit with every value.
Charting it, or not
If you have one Lp(a) result, a chart adds nothing. Keep it with the lipid panel it came from, and make sure it is easy to find. Your clinician will want it every time your cholesterol treatment is discussed.
If you have several:
- Chart one unit per line. Results in mg/dL and nmol/L belong on separate charts, or in a table, not on one axis.
- Draw the cutoffs for that unit, at 30 and 50 mg/dL or 75 and 125 nmol/L.
- Space points by date, and mark pregnancies, menopause, and medication starts.
- For a trial or a new drug, chart the baseline and every result after, all at one lab.
How to track your lab results over time has the general method for any test, and How to track your cholesterol over time covers the rest of the lipid panel.
Tracking Lp(a) in HealthViewer
HealthViewer is a lab results tracker that runs on your own computer. It imports Lp(a) from lab report PDFs, MyChart downloads, and direct connections to your health system. It treats mg/dL and nmol/L as units that cannot be converted, so a result in one is never plotted on the other’s scale. Results in mg/L are converted to mg/dL. In Trends, a result that cannot be put on the chart is left off with a note saying why, so a history with both units stays honest.
Labs name the test differently, and HealthViewer keeps names it does not recognize as their own tests. If your Lp(a) results are split across Lp(a), Lipoprotein (a), and Lipoprotein(a), combine them with Merge in the Test Catalog. Lp(a) is not in the built-in Heart tag, so add the tag in the Test Catalog to keep it with your other lipids.
Medications records when a PCSK9 inhibitor or hormone therapy started, and Trends can show those dates on the chart. The journal holds the context that is not in the lab data: a pregnancy, menopause, a change of lab, or a note that a sibling was tested.
Everything stays in an encrypted file on your computer, with no account and no cloud service. Getting Started walks through the first import.
This post is general information, not medical advice. Talk to your clinician about what your Lp(a) result means for you and your family.